Would you offer live vaccines (e.g., MMRV/measles) to patients on bispecific antibodies for multiple myeloma?
This comes up from time to time, but especially in 2025 with the multistate outbreaks and the rising adoption of bispecific antibodies (e.g., teclistamab, talquetamab, elranatamab) for multiple myeloma. Would you ever consider live vaccines? If so, what parameters would you set? E.g., CD4 counts, interval between bispecific doses, presence/absence of IVIG?
2 Answers
Mednet MemberInvited Expert
Medical Oncology · Loyola University Medical Center
Answered on
I agree with the answer here by Dr. @Dr. First Last. There are a lot of nuances, though. In regard to giving the vaccine safely and effectively, the best strategy is not to wait until patients have multiple relapses and are on bispecific therapy to vaccinate. Given the recent outbreaks of measles, i...
Join for free or sign in to see the full answer
Mednet MemberInvited Expert
Medical Oncology · University of Chicago
Answered on
The truth is that if a patient is receiving immunoglobulin replacement, they are probably protected. There isn't much utility in checking titers either, because they will be reactive when receiving IVIg. I do like CD4 counts to be above 200 to give live vaccines, and would apply the same principles ...
Join for free or sign in to see the full answer